Cat. No. 2665
Chemical Name: 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one
Biological ActivityPotent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke).
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Hewawasam et al (2003) Synthesis of water-soluble prodrugs of BMS-191011: a Maxi-K channel opener targeted for post-stroke neuroprotection. Bioorg.Med.Chem.Letts. 13 1695.
Romine et al (2007) 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca2+-activated potassium (Maki-K) channels, identification, solubility, and SAR. J.Med.Chem. 50 528. PMID: 17266205.
If you know of a relevant citation for this product please let us know.
Keywords: BMS 191011, supplier, Potent, Maxi-K, channel, openers, BKCa, KCa11, Potassium, KCa, Channels, ca2+-activated, ca2+-dependent, K+, BMS191011
Find multiple products by catalog number
New Products in this Area
Potent KCa3.1 channel blockerADWX 1
Potent and selective KV1.3 channel blockerCesium chloride
Potassium channel blocker; neuroprotective
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.